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Background: The dipeptidyl peptidase-4 inhibitor sitagliptin, a new anti-diabetic medicine, is effective in treating type
2 diabetes mellitus by increasing the activation and duration of action of glucagon-like peptide-1. Since atherosclerosis
is the main pathological feature of diabetic cardiovascular complications, it is important to investigate the
anti-atherosclerotic effect of sitagliptin and explore the relevant mechanisms.
Methods: Male apolipoprotein-E-knockout mice were randomly divided into two groups and fed either high-fat diet
(HFD) or HFD plus sitagliptin at a concentration of 0.3% for 16 weeks. Body weight, food intake, blood glucose, serum
lipids and adhesion molecules were measured. The atherosclerotic plaque area and its histological composition were
analyzed using Sudan staining and immunohistochemistry. The expression of inflammatory cytokines (monocyte
chemoattractant protein (MCP)-1 and interleukin (IL)-6) and the activation of AMP-activated protein kinase (AMPK) and
mitogen-activated protein kinase (MAPK) in the aortas were determined using quantitative polymerase chain reaction
and western blot, respectively.
Results: Mice treated with sitagliptin developed fewer atherosclerotic plaques than the control group (7.64 ± 1.98% vs
12.91 ± 1.15%, p < 0.001), particularly in the aortic arch and abdominal aorta, where plaques were decreased 1.92- and
2.74-fold, respectively (p < 0.05 and p < 0.01). Sitagliptin significantly reduced the content of collagen fiber in plaques
1.2-fold (p < 0.05). Moreover, sitagliptin significantly reduced the expression of monocyte chemoattractant protein-1
and interleukin-6 in the aorta (p < 0.01 and p < 0.05), as well as the serum levels of soluble vascular cell adhesion
molecule-1 and P-selectin (both p < 0.05). In addition, Sitagliptin induced phosphorylation of AMPK and Akt (p < 0.05
and p < 0.01), while suppressed phosphorylation of p38 and extracellular signal-regulated kinase (Erk) 1/2 (p < 0.05 and
p < 0.01) in aortas.
Conclusions: Our present study indicates that sitagliptin can reduce the area of the atherosclerotic lesion, possibly by
regulating the AMPK and MAPK pathways and then reducing leukocyte –endothelial cell interaction and inflammation
reactions. These actions are independent of weight loss and glucose-reducing effects.
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Atherosclerosis, one of the most important manifestations
and main pathological features of diabetic vascular compli-
cations, is a chronic inflammatory response in arteries that
is caused by the recruitment of blood monocytes, depos-
ition of lipids, and formation of macrophage foam cells.
Atherosclerosis remains the leading cause of morbidity and
mortality in patients with type 2 diabetes mellitus [1].
DPP-4 inhibitors are a new class of anti-diabetic drugs
that improve glucose metabolism by raising the active
concentration and duration of action of glucagon-like pep-
tide (GLP)-1 [2-5]. Sitagliptin, as one of the DPP-4 inhibi-
tors, has been reported to play a protective role in the
cardiovascular disease included atherosclerosis [6-11]. But
the mechanisms through which sitagliptin attenuate the
progress of atherosclerosis are complex and still not com-
pletely understood. It was previously reported that most of
the anti-atherosclerotic effects of GLP-1 and DPP-4 inhib-
itors may be mediated through the activation of intracellu-
lar cyclic AMP (cAMP) and protein kinase A (PKA)
signaling [6,12]. However, other studies have indicated that
DPP-4 inhibitors might protect against endothelial inflam-
mation and increase nitric oxide (NO) through other
mechanisms, independent of the cAMP/PKA or phospha-
tidylinositide 3-kinase (PI3K)/AKT pathways [13,14]. Re-
cently researches confirmed that Sitagliptin and exendin-4
can not only activate the phosphorylation of AMPK but
also inhibit the activation of MAPK including p38 and
ERK [15-18]. Activation of AMP-activated protein kinase
(AMPK), an energy sensor ubiquitously expressed in vascu-
lar cells, has been reported to possess anti-atherosclerotic
effects [19-21] by upregulating the Akt/endothelial NO syn-
thase (eNOS)/NO signaling pathway, leading to the
suppression of p38-mediated nuclear factor-κB activation
and, consequently, suppression of downstream inflamma-
tory responses [21-23]. And suppression of mitogen-
activated protein kinase (MAPK) also has been reported to
have beneficial effects in atherosclerosis through inhibiting
adhesion molecules and anti-inflammation effects, as well
as increase the stability of the carotid plaques [24-29].
Thus, based on the indication of above researches and
the proposed effects of sitagliptin, we hypothesized that
sitagliptin can inhibit the progression of atherosclerosis
possibly by activating the AMPK and suppressing the
MAPK, leading to decreases in adhesion molecules and
inflammatory cytokines. To test this hypothesis, we
conducted this comprehensive study to evaluate the
anti-atherosclerotic effect of sitagliptin and explore the
underlying mechanisms in ApoE−/− mice.
Methods
Animals and diets
ApoE−/− mice with the C57BL/6 genetic background,
provided by Joslin Diabetes Center (Boston, MA, USA),were bred in a pathogen-free environment with a 12 h
light/dark cycle and free access to food and water. We per-
formed the experimental research on animals following
internationally recognized guidelines with the approval of
an appropriate ethics committee. All experiments were
performed in the experimental animal center of Southern
Medical University, Guangzhou, China (certificate num-
ber: SCXK2011-0015) according to institutional and gov-
ernment guidelines and approved by the local council of
ethics. At the age of 8 weeks, 24 male ApoE−/− mice were
randomly divided into two groups. The control group was
fed a high-fat diet (GDLMC, Guangzhou, China) contain-
ing 21.8% fat, providing 42% energy and 1.25% cholesterol
for 16 weeks, while the experimental group was fed a
high-fat diet mixed with sitagliptin (Merck & Company,
Guangzhou, China) at a final concentration of 0.3% (corre-
sponding to 200 mg/kg/day) for the same time.Metabolic profile analysis
The body weight and food intake of animals were re-
corded weekly. An intraperitoneal glucose tolerance
test, with injection of 20% glucose at a dose of 2 g/kg,
was performed at week 14 after 8 h fasting using tail
vein blood with the One Touch Ultra (Lifescan;
Johnson & Johnson, USA) at 0, 15, 30, 60, and 120 min.
At the end of the study, all of the mice were fasted for
8 hours, and blood samples were then collected from
the orbital sinus after inhalation of CO2. Serum centri-
fuged from the blood samples was used to measure
levels of plasma lipids such as triglycerides (TG), total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL), low-density lipoprotein cholesterol (LDL), and
very low-density lipoprotein cholesterol (VLDL) using
an automatic biochemical analyzer (Dimension, USA).
In addition, serum levels of the soluble adhesion mole-
cules vascular cell adhesion molecule (VCAM)-1 and
P-selectin were determined by enzyme-linked im-
munosorbent assay (R&D Systems, UK), performed ac-
cording to the manufacturer’s instructions. Aortas and
other tissues were also collected and quickly frozen in
liquid nitrogen, and then stored at −80°C for later
analysis.Quantification of atherosclerotic lesion area
After removing the adventitial fatty tissue, aortas were
opened longitudinally from the aortic root to the renal
artery, and fixed in 10% formalin for 36 h. And then
the fixed aortas were stained with Sudan IV for 10 min,
differentiated in 70% alcohol for 15 min, and washed in
water for 30 min. To quantify area of the atheroscler-
otic lesion, the stained aortas were photographed using
a digital camera connected to a dissection microscope,
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the total aortic area by Image-Pro Plus 6.0.
Immunohistochemistry measurements of
atherosclerotic plaques
To analyze the histological composition of atherosclerotic
plaques, aortas fixed in 10% formalin after 24 h were paraf-
fin embedded and cross-sectioned. Masson’s trichrome
stain kit (Maiwei, Xiamen, China) was used to assess the
collagen fiber content of the lesions, and immunohisto-
chemistry was used to qualify the levels of vascular smooth
muscle cells and macrophage cells. Immunohistochemistry
was performed as follows: cross-sections of aortas were
incubated with goat anti-macrophage-2 antigen mouse
macrophage or anti-alpha-SMA polyclonal antibody, and
then incubated with a biotinylated secondary antibody; and
finally counterstained with hematoxylin (Bioss, Beijing,
China). All cross-sections were analyzed under an upright
microscope (Nikon, Tokyo, Japan). The expression levels of
macrophage and smooth muscle cells, as well as of collagen
fiber, were evaluated using Image-Pro Plus 6.0.Determination of inflammatory cytokine mRNA levels
through RT-PCR
SYBR green quantitative real-time polymerase chain reac-
tion (RT-PCR) was used to detect the mRNA levels of
DPP-4 and GLP-1 receptor (GLP-1R), as well as of the in-
flammatory cytokines monocyte chemoattractant protein
(MCP)-1 and interleukin (IL)-6. RNA extracted from the
aortic tissue of mice with E.Z.N.A Total RNA Kit II
(Omega, USA) was reversed to cDNA using the Prime-
Script RT reagent Kit (Takara Biotechnology, Japan) with
the following profile conditions: 37°C for 15 min, 85°C for
5 seconds, and 4°C for ever. Quantitative real-time PCR
was performed with ABI 7500 (ABI, USA) using SYBR Pre-
mix Ex Taq (Takara Biotechnology, Japan) as follows: one
cycle at 95°C for 30 min; 40 cycles at 95°C for 5 seconds
and 60°C for 34 seconds; and one cycle at 95°C for 15 sec-
onds, 60°C for 1 minute, and 95°C for 15 seconds. The rela-
tive quantification values for these gene expressions were
calculated by ΔΔCT methods and corrected using a house-
keeping gene. The primers used were as follows: glyceralde-
hyde 3-phosphate dehydrogenase(GAPDH)forward 5'-GT
GAAGCAGGCATCTGAGGG-3' and reverse 5'-CGAA
GGTG GAAGAGTGGGAGT-3'; DPP-4 forward 5'-GTC
TAAGCGAGGGGAGAGAAAC-3' and reverse 5'-CAAG
GCGGAGAAAGAAAGTG-3'; GLP-1R forward 5'-TG
ACCGACTGTTTGTTCTCTTG-3' and reverse 5'-CC
AACTTATGACCTTCTGGTGAC-3'; MCP-1 forward 5'-G
CAGCAGGTGTCCCAAAGAA-3' and reverse 5'-ATTT
ACGGGTCAACTTCACATTCAA-3'; and IL-6 forward
5'-AAAGCTGCGCAGAATGAGATG-3' and reverse 5'-
AAAGCTGCGCAGAATGAGATG-3'.Phosphorylation of AMPK and MAPK via western
blot analysis
SDS-PAGE immunoblotting was used to quantified the
phosphorylation of AMPK and MAPK signaling mole-
cules, including Akt, extracellular signal-regulated kinase
(ERK)1/2, and p38. Aortic tissues were ground on ice with
250 μl RIPA buffer per 20 mg, and then centrifuged at
12,000 g for 20 min to obtain the aortic protein. The pro-
tein abundance was detected with antibodies against
phospho-AMPK, AMPK, phospho-Akt, Akt, phospho-
p38, p38 phospho-ERK1/2, and ERK1/2 (Bioworld, USA).
And then anti-rabbit fluorescence secondary antibody was
used for chemiluminescene detection. Images were ob-
tained using infrared scanning (Odyssey, USA) and quan-
tified using GelPro32, and calculated by the ratio of
phosphorylation to the total protein level.
Statistical analysis
All data are expressed as mean ± SD. Comparisons of
means between two groups were analyzed using an un-
paired Student’s t test. p values <0.05 were considered
significant. All analyses were performed using SPSS ver-
sion 13.0 for Windows.Results
Animal data and metabolic profile
Table 1 shows the data of body weights, food intake, and
blood glucose and lipid levels of the animals. Statistical
analysis showed that there were no significant differ-
ences in body weight, food intake, or blood glucose
levels between the two groups during the period of the
experiment (Figure 1A–C). Moreover, our data indicated
that sitagliptin can significantly increase the level of
HDL (52.78 ± 5.25 vs 97.76 ± 8.56, p < 0.001), and tends
to increase the LDL cholestrerol levels in ApoE−/− mice,
whereas with no effect on TC, CHOL or VLDL com-
pared with the control group (Figure 1D).Sitagliptin reduced atherosclerotic lesion formation in
ApoE−/− mice
The Sudan IV staining results show the atherosclerotic
plaques in entire aorta, aortic arch and abdominal aorta
(Figure 2A–C). In ApoE−/− mice, the sitagliptin group
showed fewer atherosclerotic plaques than in controls
(7.64 ± 1.98% [range 4.62–10.13%] vs 12.91 ± 1.15% [range
11.55–14.37%], p < 0.001; Figure 2D). Compared with con-
trol mice, atherosclerotic plaque areas decreased respect-
ively 1.92- and 2.74-fold in the aortic root and abdominal
aorta of mice fed sitagliptin (p = 0.011 and p = 0.006;
Figure 2E, F). Our data show that sitagliptin can inhibit
the formation of atherosclerotic areas in entire aorta, aor-
tic root and abdominal aorta of ApoE−/− mice.
Table 1 Data on body weight, food intake, fasting blood glucose, and blood lipid profile in both groups
Control Sitagliptin p value
Daily food intake (g/w) 37.13 ± 3.24 37.41 ± 3.57 0.82 (NS)
Body weight pretreatment (g) 18.01 ± 1.04 17.91 ± 0.71 0.79 (NS)
Body weight (g) 32.73 ± 1.43 32.1 ± 1.32 0.28 (NS)
Fasting blood glucose (mg/dl) 109.58 ± 10.65 111.09 ± 8.30 0.76 (NS)
Total cholesterol (mg/dl) 1211.02 ± 163.79 1260.41 ± 160.12 0.55 (NS)
Triglycerides (mg/dl) 60.73 ± 15.62 58.19 ± 12.94 0.73 (NS)
HDL cholesterol (mg/dl) 52.78 ± 5.25 97.76 ± 8.56 <0.001
LDL cholesterol (mg/dl) 919.61 ± 96.49 1030.10 ± 128.70 0.07 (NS)
VLDL cholesterol (mg/dl) 789.24 ± 157.62 821.99 ± 59.54 0.60 (NS)
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglyceride; VLDL: very low-density lipoprotein. Values are expressed as mean ± SD, n = 8–12
per group.
Figure 1 Characteristics of control mice and those fed sitagliptin. There were no significant differences in body weight (A), food intake (B),
blood glucose (C), or blood lipids (D) between the two groups, except for a significantly increased HDL cholesterol level in mice in the sitagliptin
group. Data are mean ± SD, n = 12 per group.
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Figure 2 Atherosclerotic lesion formation in aortic sections from ApoE−/− mice. Sitagliptin reduced atherosclerotic lesion formation in ApoE−/−
mice. (A) Aortic en face flat from the aortic root to the renal artery stained with Sudan IV. (B) En face flat of the aortic arch. (C) Aortic en face flat of the
abdominal aorta. (D) Relative atherosclerotic lesion area of the atherosclerotic lesion to the whole aorta in the two groups. (E) Relative atherosclerotic
lesion area in the aortic arch. (F) Relative atherosclerotic lesion area in the abdominal aorta. Data are mean ± SD, n = 6. *p < 0.05, **p < 0.01 versus control.
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smooth muscle cells, as well as collagen fiber, in
atherosclerotic lesions
Aorta cross-section immunochemistry results showed that
there was significantly less collagen fiber in aortic plaques
after intervention with sitagliptin in ApoE−/− mice (49.86 ±
6.26 um2 vs 59.83 ± 5.82 um2; p < 0.05; Figure 3A, D).
The area occupied by vascular smooth muscle cells and
macrophages tended to be decreased in the sitagliptin
group compared to controls, albeit with no significant
difference in the statistical analysis (Figure 3B, C, E, F).Alterations in the composition of the atherosclerotic
area indicated that sitagliptin can change the stability of
the atherosclerotic plaque and attenuate the progress of
atherosclerosis.
Effect of sitagliptin on mRNA expression levels of DPP-4,
GLP-1R, and inflammatory cytokines in aortic tissues
We confirmed that DPP-4 and GLP-1R mRNA expression
levels in aortic tissues had no significantly differences
between the control and sitagliptin groups (p > 0.05;
Figure 4A, B). However, sitagliptin did significantly reduce
Figure 3 Effects of sitagliptin on collagen fibers, macrophages, and smooth muscle cells in atherosclerotic lesions. Cross-sections of the
aortic root were cut into slices and stained with Masson (A), anti-smooth muscle cell (B), and anti-macrophage antibody (C). The ratios occupied
by collagen fibers (D), smooth muscle cells (E), and macrophages (F) in the aortic plaque were also evaluated. Values are mean ± SD; n = 6 per
group; *p < 0.05.
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0.033; Figure 4C, D), which mediate inflammation in the
aorta. These data show that sitagliptin can inhibit inflam-
mation in aortic tissues, but with no effect on the expres-
sion of DPP-4 and GLP-1R in the aortas.Sitagliptin reduced adhesion molecule expression in serum
The expression of cell adhesion molecules can mediate
leukocyte rolling and leukocyte–endothelial cell interac-
tions during inflammation. Compared to control mice,
the serum levels of soluble VCAM-1 and P-selectin de-
creased significantly in the sitagliptin group (VCAM-1:
1163.16 ± 159.62 ng/ml vs 1365.18 ± 170.26 ng/ml, p < 0.05;
P-selectin: 232.71 ± 64.29 ng/ml vs 288 ± 44.46 ng/ml, p <
0.05; Figure 4E). This demonstrates that sitagliptin can in-
hibit the expression of adhesion molecules in serum. Such
molecules play an important role in the early formation of
atherosclerosis by mediating the adhesive attraction of
monocytes and endothelial cells.Effect of sitagliptin on the phosphorylation of the AMPK
and MAPK signaling pathways
Compared to controls, phosphorylation of AMPK and its
downstream signaling molecule Akt increased in the aortic
tissue of the sitagliptin group(p < 0.05 and p < 0.01), while
the phosphorylation of p38 and ERK1/2 decreased (p <
0.05 and p < 0.01) (Figure 5). These data show that sita-
gliptin can activate the AMPK signaling pathway and in-
hibit the MAPK signaling pathway, which have already
been shown to play a key role in anti-inflammation and
anti-atherosclerotic effects.Discussion
The main findings of this study lie in the effects of sita-
gliptin in reducing the formation of atherosclerotic le-
sion area in the aortic root and abdominal aorta, and
changing the histological composition of atherosclerotic
plaques by reducing the content of collagen fiber and
tending to reduce smooth muscle cells and macrophages
Figure 4 Sitagliptin decreases the expression of proinflammatory cytokines and serum soluble adhesive molecules in ApoE−/− mice.
Messenger (m)ribonu-cleic acid RNA (mRNA) expression levels, relative to those of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), of
dipeptidyl peptidase (DPP)-4 (A), glucagon-like peptide (GLP)-1 receptor (B), monocyte chemoattractant protein (MCP)-1 (C), and interleukin (IL)-6
(D), as measured by quantitative real-time reverse transcriptase polymerase chain reaction in aortas (n = 6 each). Values represent the fold of the mean
value measured in controls and are shown as mean ± SD; *p < 0.05, **p < 0.01. (E) Serum soluble vascular cell adhesion molecule (VCAM)-1 and
P-selectin concentrations, as detected by ELISA (n = 10). Values are mean ± SD; *p < 0.05.
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results are consistent with previous researches on the anti-
atherosclerotic effects of DPP-4 inhibitors in animals
[6-11,30-34]. It has been shown that sitagliptin is cardiopro-
tective in the diabetic Akita mouse even at low doses [32].
A pooled analysis of 25 randomised clinical trials indicate
that sitagliptin does not increase cardiovascular risk in
patients with T2DM [33]. And chronic treatment with sita-
gliptin may have cardioprotective effects in diabetes pa-
tients presenting with acute coronary syndrome [34].
Furthermore, the anti-atherosclerotic effects of sitagliptin
in this study occurred with no differences in food intake,
body weight or blood glucose levels between sitagliptin-fed
and control animals. Our results are roughly similar to
those reported by Junichi Matsubara et al., who reportedthat sitagliptin reduced atherosclerotic lesion formation in
ApoE-deficient mice independent of fasting glucose and
lipid profiles [6]. In addition, we unexpected discovered that
sitagliptin significantly increase the HDL cholesterol
levels and tends to increase the LDL cholestrerol levels
in ApoE−/− mice. HDL cholesterol has been demon-
strated to reduce the risk of atherosclerosis by multiple
pathophysiologic mechanisms [35]. And LDL has been
regarded as a positive risk for atherosclerosis when they
invade the endothelium and become oxidized. Previous
study suggests that sitagliptin is a sound agent for use
in the comprehensive treatment of patients with T2DM
because it improves not only glycemic control, but also
blood pressure and lipid profiles [36]. A systematic re-
view and meta-analysis reported that DPP-4 inhibitors
Figure 5 Effects of sitagliptin on AMPK- and AMPK-mediated Akt activation and MAPK phosphorylation in the aorta. Phosphorylative
and total protein expression of AMPK (A), Akt (C), p38 (E) and ERK1/2 (G) in the aortic tissue of ApoE−/− mice. Quantitative analysis of pAMPK/
AMPK (B), pAkt/Akt (D), pp38/p38 (F) and pERK1/2/ERK1/2 (H) in aortic tissue (n = 4 each). Values are mean ± SD; *p < 0.05, **p < 0.01.
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triglyceride levels, whereas the effect on the other lipids
concluded HDL and LDL cholesterol has not been con-
firmed yet [37]. Whether DPP-4 inhibitor has influence on
HDL and LDL cholesterol in mice remains contentious. It
has been reported that anagliptin significantly reduced
total cholesterol level especially VLDL and LDL without
affecting triglyceride level and vildagliptin analogue de-
creased plasma levels of LDL by 27% in Apoe−/− mice
[9,30]. However, some reports showed that sitagliptin has
no effect on TG, TC, LDL or HDL levels induced by HFD
in Apoe−/− mice [6,10]. Therefore, the definitive effects of
DPP-4 inhibitor include sitagliptin on the blood lipid pro-
files in mice remains contentious.
After observing the anti-atherosclerotic effect of sita-
gliptin, we then explored its relative mechanisms in fur-
ther. It has previously been reported that exendin-4, a
GLP-1R agonist, attenuates atherosclerosis through
PKA–PI3K/Akt–eNOS–p38 MAPK–JNK- dependent
pathways via a GLP-1R-dependent mechanism, withoutaffecting metabolic parameters [5,16,18,38-40]. Although
studies have shown that sitagliptin can inhibit the forma-
tion of atherosclerosis in ApoE−/− mice, the mechanisms
through which it attenuates the progress of atherosclerosis
are complex and not completely understood.
Recent evidences have shown a promising role for AMPK
in the attenuation of atherosclerosis involving vascular dys-
function and endothelial inflammation by upregulating the
Akt/eNOS signaling pathway [25,41] and suppressing the
activation of ERK1/2 in vascular tissues [24,26]. And it has
been demonstrated that mitogen-activated protein kinase
(MAPK) may play a role in anti-atherosclerosis [24-29],
and moreover alogliptin can inhibit the ERK-mediated ex-
pression of matrix metalloproteinases, which are involved
in atherosclerosis [17,30]. These informations provided im-
portant clues for our study.
Another major finding of this study is that it shows,
for the first time, that sitagliptin can activate the AMPK
pathway and inhibit MAPK signaling by increasing the
phosphorylation of AMPK and its downstream molecule
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ERK1/2 MAPK in the aorta. As a result, sitagliptin reduces
serum soluble VCAM-1 and P-selectin levels, which play
an important role in regulating the binding of leukocytes
to endothelial cells as a key initial step in the formation of
atherosclerosis, and also reduces the expression of inflam-
mation factors such as MCP-1 and IL-6. As is well know,
inflammation in the vascular endothelium and subsequent
leukocyte recruitment are initiating events in the progres-
sion of atherosclerosis.
A limitation of the current study is that we have only
demonstrated the mechanisms described in aortic tissues,
and were unable to provide direct evidence of sitagliptin
activating the AMPK and MAPK signaling pathways. An-
other limitation is that we were unable to measure the
plasma levels of active GLP-1 after ingestion. The defini-
tive mechanisms of action for sitagliptin still need further
investigation in vitro by culturing primary aortic endothe-
lial cells.
In summary, our study confirms that sitagliptin can at-
tenuate the development of atherosclerosis and alter the
composition of the atherosclerotic plaques induced by
HFD in ApoE−/− mice. In addition, the beneficial effects
of sitagliptin also contain increased HDL cholesterol and
decreased adhesion molecules as well as inflammatory cy-
tokines. Our present observations indicate that sitagliptin
has protective actions against atherosclerosis via anti-
inflammation potentially through AMPK and MAPK-
dependent mechanisms. Given that the prevention and
treatment of diabetic vascular complications remains im-
portant and challenging, sitagliptin, as an effective medi-
cine for diabetes, may open a new therapeutic window for
the treatment of atherosclerosis and related diseases.
Conclusions
Sitagliptin can reduce the atherosclerotic lesion area in
ApoE−/− mice by activating AMPK and AMPK-mediated
Akt signaling while reducing the phosphorylation of p38
and ERK1/2 MAPK. These, in turn, inhibit inflammatory
responses in the aorta, such as the release of MCP-1 and
IL-6, and the expression of the adhesion molecules VCAM-
1 and serum P-selectin. These effects are independent of
weight loss and glucose- and lipid-reducing effects.
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